The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Abstract
Several lines of evidence suggest that classic (5HT2A agonist) hallucinogens have clinically relevant effects in alcohol and drug addiction. Although recent studies have investigated the effects of psilocybin in various populations, there have been no studies on the efficacy of psilocybin for alcohol dependence. We conducted a single-group proof-of-concept study to quantify acute effects of psilocybin in alcohol-dependent participants and to provide preliminary outcome and safety data. Ten volunteers with DSM-IV alcohol dependence received orally administered psilocybin in one or two supervised sessions in addition to Motivational Enhancement Therapy and therapy sessions devoted to preparation for and debriefing from the psilocybin sessions. Participants’ responses to psilocybin were qualitatively similar to those described in other populations. Abstinence did not increase significantly in the first 4 weeks of treatment (when participants had not yet received psilocybin), but increased significantly following psilocybin administration ( p < 0.05). Gains were largely maintained at follow-up to 36 weeks. The intensity of effects in the first psilocybin session (at week 4) strongly predicted change in drinking during weeks 5–8 ( r = 0.76 to r = 0.89) and also predicted decreases in craving and increases in abstinence self-efficacy during week 5. There were no significant treatment-related adverse events. These preliminary findings provide a strong rationale for controlled trials with larger samples to investigate efficacy and mechanisms. TRIAL REGISTRATION: NCT02061293
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most of this research has been carried out with the Revised Mystical Experience Questionnaire 30 (MEQ30), where a high score correlates with and has been suggested as a predictor of long-term positive therapeutic outcomes in various clinical and naturalistic studies of psychedelics.”
From Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics (2024) · cites this paper as Bogenschutz et al., 2015
In the citing paper
“Assessing the subjective effects of psychedelics is essential since much research has indicated an association between the characteristic psychedelic experience and a positive effect on the symptomatology of several psychiatric illnesses.”
From Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics (2024) · cites this paper as Bogenschutz et al., 2015
In the citing paper
“Many patients describe psychedelic-induced “peak” or “mystical” experiences as being among the most meaningful events of their lives, and the intensity of these events correlates with therapeutic responses (40, 220–226).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [221]
In the citing paper
“Across psychiatric diagnoses, PAT clinical trials have suggested a relationship between the quality of the acute psychedelic experience and clinical ameliorations [36, 53, 54].”
In the citing paper
“phase I and II studies suggest a dose-dependent effect on the quality of the psychedelic experience [54, 76]”
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Schwartz, S. H. (1992) · Advances in Experimental Social Psychology · doi:10.1016/s0065-2601(08)60281-6 · Cited by 14,619
The varieties of religious experience: A study in human nature.
James, W. (1902) · doi:10.1037/10004-000 · Cited by 5,204
Motivational Interviewing: Helping People Change
Tober, G. (2013) · Alcohol and Alcoholism · doi:10.1093/alcalc/agt010 · Cited by 4,268
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
McNair, D. M. (1992) · Medical Entomology and Zoology · Cited by 2,692
Morris, S. B., & DeShon, R. P. (2002) · Psychological Methods · doi:10.1037/1082-989x.7.1.105 · Cited by 2,502
(2013) · Cited by 2,393
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988
Research works printed but not linked: 13
- Anisman H, 2008, J Psychiatry Neurosci, 33, 131
- Buckholtz NS, 1990, Neuropsychopharmacology, 3, 137
- Fetzer Institute, 1999, Multidimensional Measurement of Religiousness/Spirituality for Use in Health Research
- First MB, 1996, Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (Scid-I/P, Version 2.0)
- First MB, 1997, Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition
- Grof S, 2008, LSD Psychotherapy
- Leuner H, 1967, The Use of LSD in Psychotherapy and Alcoholism, 101
- Pahnke WN, 1969, Int Psychiatry Clin, 5, 149
- Pahnke WN, 1969, Curr Psychiatr Ther, 9, 144
- Richards WA, 1975, Counseling, peak experiences and the human encounter with death: An empirical study of the efficacy of DPT-assisted counseling in enhancing the quality of life of persons with terminal cancer and their closest family members
- Schwartz SH, 2006, Revue française de sociologie, 42, 249
- Sherwood JN, 1962, J Neuropsychiatr, 4, 69
- Wiesbeck GA, 1999, Alcohol Clin Exp Res, 23, 230
Cited by
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
“These investigators carried out an open-label proof-of-concept trial of psilocybin treatment in a sample of 10 volunteers with a DSM-IV diagnosis of alcohol dependence (Bogenschutz et al., 2014).”
BackgroundRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
“…corroborated by recent open-label trials using psilocybin-assisted psychotherapy to treat tobacco addiction (Garcia-Romeu et al., 2014; Johnson et al., 2014) and alcoholism (Bogenschutz et al., 2015) showing significant correlations between the mystical experience and improved clinical outcomes.”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
“19 Signifi cantly decreased anxiety and depression scores were observed 3 and 6 months after a single dose of psilocybin in patients with anxiety related to end-stage cancer, 15 and improve ments in wellbeing lasting for more than 1 year were observed in healthy individuals given a single dose of…”
BackgroundEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
“Evidence from a series of recent small-scale studies (Moreno et al., 2006; Grob et al., 2011; Gasser et al., 2014; Bogenschutz et al., 2015; Osório Fde et al., 2015; Carhart-Harris et al., 2016a, 2018a; Griffiths et al., 2016; Ross et al., 2016; Palhano-Fontes et al., 2019), in addition to…”
Background
Metadata
- Authors
- Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J.
- Affiliations
- University of New Mexico Health Sciences Center (US)
- Department of Psychiatry, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
- Universidade Estadual de Santa Cruz (BR)
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2015-01-13
- Volume
- 29
- Issue
- 3
- Pages
- 289-299
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2075238613
- Cited by
- 1,151
- References
- 94
- Citations by year
- 2026: 73 · 2025: 154 · 2024: 152 · 2023: 156 · 2022: 161 · 2021: 137 · 2020: 105 · 2019: 46 · 2018: 64 · 2017: 43 · 2016: 47 · 2015: 11
- FWCI
- 68.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- UNM’s Digital Repository (University of New Mexico) (submittedVersion)
- Funders
- Johns Hopkins University
- Heffter Research Institute
- Lundbeckfonden
- National Institutes of Health
- National Center for Research Resources (UL1RR031977)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- psilocybin, alcoholism, hallucinogens, motivational enhancement therapy, alcohol abstinence, craving, abstinence self-efficacy, treatment safety
- MeSH terms
- Adult, Alcohol Drinking, Alcoholism, Combined Modality Therapy, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Motivation, Psilocybin, Time Factors, Cognitive Behavioral Therapy, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. https://app.cochat.ai/papers/10.1177/0269881114565144
- The paper
- Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology. https://doi.org/10.1177/0269881114565144
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.